How to buy immatics biotechnologies GmbH stock | $3.84

immatics biotechnologies GmbH is a business based in the US. immatics biotechnologies GmbH shares (IMTXW) are listed on the NASDAQ and all prices are listed in US Dollars. immatics biotechnologies GmbH employs 134 staff and has a market cap (total outstanding shares value) of 0.00.

immatics biotechnologies GmbH stock price (NASDAQ: IMTXW)

Use our graph to track the performance of IMTXW stocks over time.

immatics biotechnologies GmbH shares at a glance

• Key figures

Information last updated 2021-08-09.

Latest market close	$3.84
52-week range	$2.26 - $5.55
50-day moving average	$0.00
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy immatics biotechnologies GmbH shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy immatics biotechnologies GmbH stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

immatics biotechnologies GmbH price performance over time

Historical closes compared with the close of $3.84 from 2021-10-19

1 week (2021-10-13)	-8.79%
1 month (2021-09-20)	-8.13%
3 months (2021-07-20)	13.61%
6 months (2021-04-20)	11.63%

1 year (2020-10-20)	29.73%
2 years (2019-10-16)	N/A
3 years (2018-10-16)	N/A
5 years (2016-10-16)	N/A

immatics biotechnologies GmbH financials

Gross profit TTM	$0
Return on assets TTM	0%
Return on equity TTM	0%
Profit margin	-156.4%
Book value	N/A
Market capitalisation	$673 million

TTM: trailing 12 months

Shorting immatics biotechnologies GmbH shares

There are currently 3,846 immatics biotechnologies GmbH shares held short by investors – that's known as immatics biotechnologies GmbH's "short interest". This figure is 48.3% down from 7,439 last month.

There are a few different ways that this level of interest in shorting immatics biotechnologies GmbH shares can be evaluated.

immatics biotechnologies GmbH's "short interest ratio" (SIR)

immatics biotechnologies GmbH's "short interest ratio" (SIR) is the quantity of immatics biotechnologies GmbH shares currently shorted divided by the average quantity of immatics biotechnologies GmbH shares traded daily (recently around inf billion). immatics biotechnologies GmbH's SIR currently stands at 0. In other words for every 100,000 immatics biotechnologies GmbH shares traded daily on the market, roughly 0 shares are currently held short.

However immatics biotechnologies GmbH's short interest can also be evaluated against the total number of immatics biotechnologies GmbH shares, or, against the total number of tradable immatics biotechnologies GmbH shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case immatics biotechnologies GmbH's short interest could be expressed as 0% of the outstanding shares (for every 100,000 immatics biotechnologies GmbH shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable immatics biotechnologies GmbH shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against immatics biotechnologies GmbH.

Find out more about how you can short immatics biotechnologies GmbH stock.

immatics biotechnologies GmbH share dividends

We're not expecting immatics biotechnologies GmbH to pay a dividend over the next 12 months.

immatics biotechnologies GmbH overview

Immatics N. V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors through two distinct therapeutic modalities, such as Adoptive Cell Therapies and antibody-like TCR Bispecifics. Its pipeline comprises of eight therapeutic programs, of which four are in clinical trials and four are in preclinical development. The company is based in Tuebingen, Germany. .

Frequently asked questions

How many people work for immatics biotechnologies GmbH?
Latest data suggests 134 work at immatics biotechnologies GmbH. Where is immatics biotechnologies GmbH based?
immatics biotechnologies GmbH's address is: Paul-Ehrlich-Str. 15, Tuebingen, Germany, 72076